Revamped Amneal Would Consider A Transformational Deal
Amneal’s new management team is open to negotiating a major transaction, even as it looks to restore organic growth through a greater focus on differentiated generic and hybrid products.
You may also be interested in...
Amneal Takes Control Of AvKARE In US
Amneal has acquired a majority stake in manufacturer and wholesaler AvKARE, giving the firm access to the “large, complex and growing federal healthcare market.”
Deal Watch: Aevi Options AstraZeneca Antibody For Rare Disease
Aevi needs to raise funds first, but hopes to develop MEDI2338 for adult-onset Still’s disease. Also, Alnylam plans to leverage Ironwood’s GI expertise for givosiran in acute hepatic porphyria and Ultragenyx snags option to buy GeneTx.
Dr Reddy's Is Knocked Back On US NuvaRing And Copaxone Rivals
Dr Reddy’s has received a further CRL from the US Food and Drug Administration over its application for a generic rival to Merck Sharp & Dohme’s NuvaRing contraceptive, along with a CRL for its version of Teva’s Copaxone.